Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1/CTLA-4”

217 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 217 results

Testing effectiveness (Phase 2)UnknownNCT06406673
What this trial is testing

A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Who this might be right for
Extensive Small Cell Lung Cancer
Henan Cancer Hospital 70
Early research (Phase 1)Ended earlyNCT03580694
What this trial is testing

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Regeneron Pharmaceuticals 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07243951
What this trial is testing

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Who this might be right for
Combined Hepatocellular-cholangiocarcinomaLiver Neoplasms
Shanghai Zhongshan Hospital 75
Large-scale testing (Phase 3)Ended earlyNCT03515629
What this trial is testing

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 5
Testing effectiveness (Phase 2)UnknownNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT05608044
What this trial is testing

Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Agenus Inc. 234
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253
What this trial is testing

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Who this might be right for
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University 47
Testing effectiveness (Phase 2)Looking for participantsNCT07315854
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07533305
What this trial is testing

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
QL1706ESCCFirst-line Therapy
The First Affiliated Hospital of Henan University of Science and Technology 50
Not applicableStudy completedNCT03549546
What this trial is testing

Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

Who this might be right for
Lung CancerSurgery
Centre Hospitalier Universitaire de Saint Etienne 31
Testing effectiveness (Phase 2)UnknownNCT05430906
What this trial is testing

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hunan Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT05492123
What this trial is testing

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Who this might be right for
Uterine Cervical Neoplasms
Hospital Israelita Albert Einstein 112
Testing effectiveness (Phase 2)Looking for participantsNCT07289997
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Who this might be right for
AFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4AFPGC+1 more
Hebei Medical University Fourth Hospital 39
Large-scale testing (Phase 3)Looking for participantsNCT03949231
What this trial is testing

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

Who this might be right for
Liver Cancer
Second Affiliated Hospital of Guangzhou Medical University 200
Testing effectiveness (Phase 2)Looking for participantsNCT07290010
What this trial is testing

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital 25
Not applicableLooking for participantsNCT05332925
What this trial is testing

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Who this might be right for
Lung CancerNSCLCNSCLC Stage IV
Jun Zhang, MD, PhD 25
Large-scale testing (Phase 3)Looking for participantsNCT06749899
What this trial is testing

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center 580
Early research (Phase 1)Active Not RecruitingNCT04117087
What this trial is testing

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Who this might be right for
Colorectal CancerPancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27
Testing effectiveness (Phase 2)UnknownNCT05901584
What this trial is testing

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Who this might be right for
ImmunotherapySecond-line Treatment
Second Affiliated Hospital of Zunyi Medical University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05529316
What this trial is testing

Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Who this might be right for
Advanced Melanoma
Agenus Inc. 150
Next Page